World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

New report: CivicaScript saved patients & payers more than $16 million in generic medicine costs in 2025

Cision PR Newswire by Cision PR Newswire
June 25, 2026
in Press Releases - Lifestyle
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

Nonprofit pharmaceutical company has delivered nearly $44 million in savings since 2022

LEHI, Utah, June 25, 2026 /PRNewswire/ — CivicaScript’s transparent, nonprofit business model saved patients and payer members more than $16 million in 2025 after they switched to its low-cost generic medicines, the company’s new Annual Savings Report shows. Patients saved as much as 91% per claim.


CivicaScript is bringing unprecedented transparency to the drug supply chain to make quality generic medicines affordable and available for everyone. A not-for-profit company, CivicaScript is committed to providing affordable, essential generic medicines and biosimilars to promote the social welfare and health of the community.

Since the launch of its first product in 2022, CivicaScript has delivered nearly $44 million in savings to patients and its payer members.

The 2025 savings were driven by CivicaScript’s first product, abiraterone acetate tablets USP, 250 mg, and four additional specialty generics launched that year. The new report shows that while conversion to CivicaScript’s newer products is still in early stages, the products are already driving significant per claim savings.

Meanwhile, the continued growth of CivicaScript abiraterone (now sold under the proprietary name Abirtega®) underscores the ongoing need for the company’s unique business model.

“CivicaScript was created to bring affordability and transparency to the generic and biosimilar drug market,” said CivicaScript President Brent J. Eberle. “This report demonstrates the substantial savings that can be achieved when manufacturers, payers and pharmacies work together to put patients first.”

CivicaScript expects savings to continue to grow as additional products gain adoption and its new therapies enter the market. Earlier this year, the organization expanded into biosimilars with the launch of a low-cost private-label insulin glargine and exclusive distribution of ustekinumab-aauz,1 a biosimilar to Stelara®2. Civica insulin is available nationwide; in California, it is sold under the CalRx®3 brand.

Key 2025 savings data

Patients who used CivicaScript medicines in 2025 saved more than $400,000 in out-of-pocket pharmacy costs. Per claim savings varied by product and product strength; the highest average per claim savings for patients was $56 (for droxidopa capsules, 300 mg).

CivicaScript payer members, who bear a larger share of total medicine costs, saw $15.7 million in savings in 2025. On average, payers saved $856/claim with abiraterone – the company’s most utilized product — and $80/claim to $2,358/claim for its four newer products.

CivicaScript is a nonprofit pharmaceutical company created in 2020 to lower the prices of prohibitively expensive generic medicines. The company’s business model is to manufacture low-cost generic medicines, then work with payers, PBMs and pharmacies across the country to pass along the cost savings to patients. The model focuses on transparency and collaboration throughout the value chain from manufacturing through dispensing — with every stakeholder along the way knowing the price of the medicine and driving savings through to the patient.

CivicaScript’s MaxRP® policy is its maximum recommended price to the consumer. Information on every CivicaScript product package enables healthcare providers, caregivers, patients and others to compare prices and confirm they are being charged no more than the MaxRP.

“At a time when too many families are facing rising prescription drug costs, our partnership with CivicaScript is delivering on a simple, but powerful, promise to make essential generic medicines more affordable,” said Sean Robbins, EVP and Chief Operating Officer at Blue Cross Blue Shield Association. “By advancing a transparent model that puts patients first, we’re helping reshape the marketplace to bring more competition, lower costs and improve access for the people who need these medicines most.”

About the analysis
The report analyzed pharmacy claims data from January 1 through December 31, 2025, from each CivicaScript member. The report reflects the savings from CivicaScript products as of their first full quarter of availability.

1 Ustekinumab-aauz injection, 45 mg/0.5mL and 90 mg/mL
2 Stelara® is a registered trademark of Johnson & Johnson.
3 CalRx® is a registered trademark of the California Department of Health Care Access and Information.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/new-report-civicascript-saved-patients–payers-more-than-16-million-in-generic-medicine-costs-in-2025-302809895.html

SOURCE Civica Rx

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • Thunes Expands Real-Time Payouts to Bhutan, Unlocking the Nation’s Remittance Market

    0 shares
    Share 0 Tweet 0
  • Bloomberg Indices and HKEX Launch Co-branded Offshore RMB Bond Index Family to Support Growing Investor Demand in the Dim Sum Bond Market

    0 shares
    Share 0 Tweet 0
  • CANACCORD GENUITY GROUP INC. ANNOUNCES SALE OF ITS WEALTH MANAGEMENT BUSINESS IN THE UK & CROWN DEPENDENCIES TO CENTERBRIDGE PARTNERS, L.P. AND MUBADALA INVESTMENT COMPANY PJSC

    0 shares
    Share 0 Tweet 0
  • SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Portillo’s Inc. (NASDAQ: PTLO) — Investors Who Suffered Losses Are Encouraged to Contact the Firm.

    0 shares
    Share 0 Tweet 0
  • EFICYENT to Join Banks and Fintech Companies at Singapore FinTech Festival 2026

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler